Take a look at the news making top headlines during the month of November on dicardiology.com

November was a busy month with many FDA approvals and breaking clinical trial results. Take a look at the news making top headlines that you might have missed during the month of November.

1. BLOG: Cryoablation Gets New Tech

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular research organization, has announced the publication of original research focused on health equity and outcomes in the fourth trimester of pregnancy (defined as the first 12 weeks postpartum/after delivery).

As coronary computed tomography angiography (CCTA) progresses towards becoming the primary imaging modality for not only diagnostic purposes, but also for clinical trial endpoints, there is a need to address the requirements for generating high-quality CCTA image data to ensure accurate and robust CAD assessments

Coronary artery disease (CAD), also known as ischemic heart disease, is the most common heart disease with a prevalence in the United States of approximately 7% in people 20 years and older (1).

December 1, 2023 — As the use of wearable technology grows, smartwatches are marketed across the globe to consumers as a way to monitor health. 

For some, they’re told by these devices that they have atrial fibrillation, an irregular heartbeat, which is known to increase the risk of heart attack and stroke. 

December 1, 2023 — Researchers have succeeded in restoring lost brain function in mouse models of stroke using small molecules that in the future could potentially be developed into a stroke recovery therapy.

November 30, 2023 — Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

November 30, 2023 —  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all three patients from the non-randomized cohort of the 

November 29, 2023 —  Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now